LeMaitre Vascular, Inc. (LMAT) News
Follow LeMaitre Vascular, Inc. (LMAT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
LeMaitre to participate in investor conferences in September
LeMaitre said it will participate in upcoming investor conferences in September.
EQUITY | Aug 27, 2026, 08:51 PM UTC
L
LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 Est; Lowers FY2026 Sales Guidance from $277.000M
LeMaitre Vascular (NASDAQ: LMAT ) lowers FY2026 GAAP EPS guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 analyst estimate. Lowers FY2026 sales outlook from $277.000 million-$283.000 million to $274.300 million-$278.300
EARNINGS | Aug 04, 2026, 08:25 PM UTC
L
LMAT - LeMaitre Q2 2026 Financial Results
LMAT - LeMaitre Q2 2026 Financial Results
EARNINGS | Aug 04, 2026, 08:07 PM UTC
L
LMAT - Over the weekend Herb Greenberg published a negative piece on Lemaitre Vascular: "Red Flag Alert – The 'Pricing' of Success for Lemai
LMAT - Over the weekend Herb Greenberg published a negative piece on Lemaitre Vascular: "Red Flag Alert – The 'Pricing' of Success for Lemaitre. Valued as a growing, durable Medtech compounder, but has its model met its
EQUITY | Jul 20, 2026, 12:13 PM UTC